Portal de investigación
MS201944-0170: A phase Ila study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Ciardiello, Fortunato
- Dols, Manuel Cobo
- Paz-Ares, Luis G.
- Carpeno, Javier de Castro
- Felip, Enriqueta
- Campelo, Rosario Garcia
- Losonczy, Gyorgy
- Szalai, Zsuzsanna
- Vicente, David
- Schroder, Andreas
- Beier, Frank
- Bhandge, Prasad
- Galffy, Gabriella
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0732-183X, 1527-7755
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 10,054 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF CLINICAL ONCOLOGY LIPPINCOTT WILLIAMS & WILKINS
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Ciardiello,F,Dols,MC,Vidal,OJ,Paz,LG,Carpeno,JC,Felip,E,Campelo,RG et al. MS201944-0170: A phase Ila study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2019. Chicago-IL. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2019.